


CAN508

Cat. No.:	HY-100429
CAS No.:	140651-18-9
Molecular Formula:	C ₉ H ₁₀ N ₆ O
Molecular Weight:	218.22
Target:	CDK
Pathway:	Cell Cycle/DNA Damage
Storage:	4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



SOLVENT & SOLUBILITY

In Vitro	DMSO : 250 mg/mL (1145.63 mM; Need ultrasonic)				
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	
				5 mg	
				10 mg	
				10 mM	
			1 mg	5 mg	10 mg
	1 mM		4.5825 mL	22.9127 mL	45.8253 mL
	5 mM		0.9165 mL	4.5825 mL	9.1651 mL
	10 mM		0.4583 mL	2.2913 mL	4.5825 mL
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (9.53 mM); Clear solution				

BIOLOGICAL ACTIVITY

Description	CAN508 is a potent, ATP-competitive CDK9/cyclin T1 inhibitor with an IC ₅₀ of 0.35 μM. CAN508 exhibits a 38-fold selectivity for CDK9/cyclin T over other CDK/cyclin complexes. Antitumor activity ^{[1][2]} .			
IC ₅₀ & Target	CDK9/cyclin T1 0.35 μM (IC ₅₀)	CDK2/cyclin E 20 μM (IC ₅₀)	cdk2/cyclin A 69 μM (IC ₅₀)	Cdk4/cyclin D1 13.5 μM (IC ₅₀)
	CDK7/cyclin H 26 μM (IC ₅₀)	Cdk1/cyclin B 44 μM (IC ₅₀)		
In Vitro	<p>CAN508 reduces the frequency of S-phase cells of the cancer cell line HT-29 in antiproliferation assays^[1].</p> <p>CAN508 (20-40 μM; 72 hours) significantly reduces cell proliferation in a dose dependent manner in all three esophageal adenocarcinoma cell lines (SKGT4, OE33 and FLO-1 cells) with IC₅₀s ranging from 34.99 to 91.09 μM^[2].</p> <p>CAN508 (40 μM; 72 hours) increases apoptosis in all three esophageal adenocarcinoma cells^[2].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>			

	Apoptosis Analysis ^[1]
Cell Line:	SKGT4, OE33 and FLO-1 cells
Concentration:	40 μ M
Incubation Time:	72 hours
Result:	Increased apoptosis by 2 fold in all three esophageal adenocarcinoma cells compared to untreated controls.
In Vivo	CAN508 (60 mg/kg; i.p.; daily for 10 days) has antitumor effects in esophageal adenocarcinoma xenografts ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model:	4 weeks-old female nude mice (esophageal adenocarcinoma xenografts) ^[1]
Dosage:	60 mg/kg
Administration:	I.p.; daily for 10 days
Result:	Caused reduction of tumor growth starting from post-treatment day three with 50.83% reduction.

CUSTOMER VALIDATION

- Universidade de Lisboa. 2021 Dec 21.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Krystof V, et al. 4-arylo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006;49(22):6500-6509.

[2]. Tong Z, et al. Antitumor effects of cyclin dependent kinase 9 inhibition in esophageal adenocarcinoma. Oncotarget. 2017;8(17):28696-28710.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA